These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 5041348

  • 1. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F, Gaillard JM, Eisenring JJ, Krassoievitch M, Yanniotis G, Tissot R.
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract] [Full Text] [Related]

  • 2. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN.
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract] [Full Text] [Related]

  • 3. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD, Lee JE, McDowell F.
    Trans Am Neurol Assoc; 1971 Dec; 96():59-65. PubMed ID: 5159130
    [No Abstract] [Full Text] [Related]

  • 4. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Gauthier G, de Ajuriaguerra J, Simona B, Constantinidis J, Eisenring JJ, Krassoievitch M, Yanniotis G, Tissot R.
    Rev Neurol (Paris); 1970 Nov; 123(5):297-319. PubMed ID: 5513630
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Methyldopa and levodopa].
    Chang CP.
    Zhonghua Yi Xue Za Zhi; 1974 Nov; 7():439-41. PubMed ID: 4211508
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL, Ringel SP.
    Confin Neurol; 1973 Nov; 35(3):186-92. PubMed ID: 4712885
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Modification of Parkinsonism--chronic treatment with L-dopa.
    Cotzias GC, Papavasiliou PS, Gellene R.
    N Engl J Med; 1969 Feb 13; 280(7):337-45. PubMed ID: 4178641
    [No Abstract] [Full Text] [Related]

  • 11. Therapeutic uses and side effects of L-dopa.
    Boshes B.
    Adv Intern Med; 1972 Feb 13; 18():219-49. PubMed ID: 4576081
    [No Abstract] [Full Text] [Related]

  • 12. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N, Kito S, Yamamoto M, Itoga E, Kosaka K.
    Nihon Rinsho; 1974 Mar 13; 32(3):579-86. PubMed ID: 4859014
    [No Abstract] [Full Text] [Related]

  • 13. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A, Casacchia M, Reitano M, Ruggieri S, Barba C, Zamponi A.
    Minerva Med; 1972 Dec 12; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract] [Full Text] [Related]

  • 14. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W, Butz P, Wiesendanger M.
    Dtsch Z Nervenheilkd; 1970 Dec 12; 197(1):85-100. PubMed ID: 5522871
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Siegfried J.
    Rev Neurol (Paris); 1970 Apr 12; 122(4):243-8. PubMed ID: 5472041
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
    Geissbuhler F, Eisenring JJ, Friedli P, Bartholini G, Tissot R.
    Encephale; 1972 Apr 12; 61(2):127-48. PubMed ID: 4634903
    [No Abstract] [Full Text] [Related]

  • 20. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R, Bartholini G, Constantinidis J, Eisenring JJ, Geissbühler F, Yanniotis G, de Ajuriaguerra J.
    Schweiz Med Wochenschr; 1973 Oct 20; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.